CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Teduglutide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02431325
NCT02431325Phase 2Completed

A Study to Investigate Gastrointestinal Epithelial Integrity and Arterial Inflammation in Individuals With and Without HIV

Massachusetts General Hospital·interventional·Posted May 1, 2015·Updated Jun 12, 2023

In Brief

A Phase 2 clinical trial evaluating Teduglutide and Placebo for HIV. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The purpose of this research study is to determine whether teduglutide can repair a "leaky" gut, decrease inflammation, and prevent or treat plaque, a build-up of fat and other materials in the blood vessels of the heart, in people with HIV. HIV disease is linked to inflammatory changes and leakiness of the gut. These changes or conditions may increase the risk of developing heart and blood vessel disease. The investigators believe teduglutide can help repair the gut barrier in people with HIV, leading to a decrease in inflammation and plaque in the blood vessels of the heart.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesUnited States

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 1, 2015
Enrollment StartDec 1, 2015
Primary CompletionJan 21, 2020
Study CompletionJan 21, 2021
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 11.2 years ago

Interventions

Teduglutidedrug

Placebodrug